Global X Genomics & Biotechnology UCITS ETFGlobal X Genomics & Biotechnology UCITS ETFGlobal X Genomics & Biotechnology UCITS ETF

Global X Genomics & Biotechnology UCITS ETF

No trades

Key stats


Assets under management (AUM)
‪15.16 M‬GBP
Fund flows (1Y)
‪5.81 M‬GBP
Dividend yield (indicated)
Discount/Premium to NAV
1.2%
Shares outstanding
‪2.54 M‬
Expense ratio
0.60%

About Global X Genomics & Biotechnology UCITS ETF


Issuer
Mirae Asset Global Investments Co., Ltd.
Brand
Global X
Inception date
Nov 2, 2021
Index tracked
Solactive Genomics v2 Index - Benchmark TR Net
Replication method
Physical
Management style
Passive
Dividend treatment
Capitalizes
Primary advisor
Carne Global Fund Managers (Ireland) Ltd.
Identifiers
2
ISIN IE00BM8R0N95
The Funds investment objective is to generate returns that closely correspond, before fees and expenses, generally to the price and yield performance of the Solactive Genomics v2 Index

Classification


Asset Class
Equity
Category
Sector
Focus
Theme
Niche
Genomic advancements
Strategy
Vanilla
Geography
Global
Weighting scheme
Market cap
Selection criteria
Market cap

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of February 12, 2026
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.76%
Health Technology91.53%
Health Services8.23%
Bonds, Cash & Other0.24%
Cash0.24%
Stock breakdown by region
82%14%3%
North America82.77%
Europe14.19%
Asia3.04%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows



Frequently Asked Questions


GNOG invests in stocks. The fund's major sectors are Health Technology, with 91.53% stocks, and Health Services, with 8.23% of the basket. The assets are mostly located in the North America region.
GNOG top holdings are Praxis Precision Medicines, Inc. and Moderna, Inc., occupying 6.46% and 6.16% of the portfolio correspondingly.
GNOG assets under management is ‪15.16 M‬ GBP. It's risen 2.07% over the last month.
GNOG fund flows account for ‪5.81 M‬ GBP (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, GNOG doesn't pay dividends to its holders.
GNOG shares are issued by Mirae Asset Global Investments Co., Ltd. under the brand Global X. The ETF was launched on Nov 2, 2021, and its management style is Passive.
GNOG expense ratio is 0.60% meaning you'd have to pay 0.60% of your investment to help manage the fund.
GNOG follows the Solactive Genomics v2 Index - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
GNOG invests in stocks.
GNOG price has fallen by −4.35% over the last month, and its yearly performance shows a 12.03% increase. See more dynamics on GNOG price chart.
NAV returns, another gauge of an ETF dynamics, have risen by −4.33% over the last month, have fallen by −4.33% over the last month, showed a 1.82% increase in three-month performance and has increased by 10.69% in a year.
GNOG trades at a premium (1.25%) meaning the ETF is trading at a higher price than the calculated NAV.